title: Preclinical evaluation of Oxygent as an adjunct to radiotherapy.
abstract: These studies examine the potential value of a concentrated emulsion of perfluorooctylbromide (perflubron; Oxygent, Alliance Pharmaceutical Corp.) as an adjunct to radiotherapy. The effects of Oxygent on solid tumors were examined using EMT6 mammary tumors in BALB/c mice and BA1112 rhabdomyosarcomas in WAG/rij rats. Treatment with Oxygent plus O2, carbogen (95% O2/5% CO2), or hyperbaric oxygen (HBO) increased the effects of radiation on the tumors. Analyses of tumor cell survival curves and measurements of intratumor pO2 showed that this potentiation reflected an increase in the proportion of well-oxygenated tumor cells. Neither treatment of the animals with carbogen, O2, or HBO alone nor treatment of air-breathing rodents with Oxygent produced changes of similar magnitude. Treatment with a vehicle emulsion containing all the components of Oxygent except the perflubron did not alter tumor radiosensitivity, showing that tumor radiosensitization required the oxygen-transporting perfluorocarbon, and did not result from any biologic or physiologic effects of other components of the emulsion. These studies also examined the effects of Oxygent on the radiation responses of mouse skin and bone marrow. Oxygent selectively increased the radiation sensitivity of tumors relative to these normal tissues, thereby increasing the therapeutic ratio and producing therapeutic gain. Oxygent appears to warrant further testing as an adjunct to cancer therapy.
authors.affiliation: Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06510-8040.
authors.forename: S
authors.initials: S
authors.lastname: Rockwell
authors.forename: M
authors.initials: M
authors.lastname: Kelley
authors.forename: C G
authors.initials: CG
authors.lastname: Irvin
authors.forename: C S
authors.initials: CS
authors.lastname: Hughes
authors.forename: H
authors.initials: H
authors.lastname: Yabuki
authors.forename: E
authors.initials: E
authors.lastname: Porter
authors.forename: J J
authors.initials: JJ
authors.lastname: Fischer
mesh_terms: D000818:Animals; D001802:Blood Substitutes / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004655:Emulsions; D005069:Evaluation Studies as Topic; D005466:Fluorocarbons / Q000627:therapeutic use*; D006842:Hydrocarbons, Brominated; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000532:radiotherapy / Q000628:therapy*; D010100:Oxygen; D011836:Radiation Tolerance / Q000187:drug effects; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D051381:Rats
chemical_list: D001802:Blood Substitutes; D004655:Emulsions; D005466:Fluorocarbons; D006842:Hydrocarbons, Brominated; D011838:Radiation-Sensitizing Agents; C003072:perflubron; D010100:Oxygen